Continuous and high‐dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study
Pediatric Blood & Cancer2010Vol. 57(1), pp. 36–40
Citations Over TimeTop 19% of 2010 papers
Takashi Taga, Yasuto Shimomura, Yasuo Horikoshi, Atsushi Ogawa, Masaki Itoh, Masahiko Okada, Junichi Ueyama, Takeshi Higa, Arata Watanabe, Hirokazu Kanegane, Asayuki Iwai, Yutaka Saiwakawa, Kazuhiro Kogawa, Junko Yamanaka, Masahito Tsurusawa
Abstract
Continuous and high-dose cytarabine combined chemotherapy with reduced intensity would be effective in DS children with AML.
Related Papers
- → Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine(2001)214 cited
- → Mitoxantrone(1996)47 cited
- → Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia(1991)23 cited
- → High-dose mitoxantrone in acute leukaemia: New York Medical College experience(1997)2 cited
- → Continuous Infusion of Mitoxantrone Combined with High Dose Cytarabine (c-HAM) in de Novo AML(1998)